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Contrast-Aided Diagnostic Ultrasound
Does Not Enhance Lung Metastasis in
a Mouse Melanoma Tumor Model
Douglas L. Miller, PhD, Chunyan Dou, MD
Objective. The purpose of this research was to test the hypothesis that contrast-aided diagnostic ultra-
sound (CADUS) could exacerbate the metastatic spread of mouse melanoma tumor cells to the lungs.
Methods. The melanoma cell lines B16 and B16-D5 (metastatic specifically to lung) were implanted
on a hind leg of female C57/bl6 mice. Growing tumors were scanned by 1.5-MHz diagnostic ultra-
sound in a 37°C water bath. Four hundred image frames were triggered at a 1-Hz rate with 4 retro-
orbital injections of an ultrasonographic contrast agent at dosage of 10 µL/kg at 100-second intervals.
Sham-treated mice received 400 frames of ultrasonography followed by the contrast agent with the
ultrasound off. The primary tumor was surgically removed 1 day after ultrasound administration. Lungs
were removed and evaluated blind after 2 weeks of bleaching in Fekete solution. Results. Three exper-
iments were performed. The first experiment involved scanning sham and CADUS groups of 20 mice
each with B16 tumors; B16 metastasis was not enhanced. The second experiment repeated this test
with the D5 cell line; the metastasis enhancement was marginally significant for average number (0.3
and 3.2; P = .06) and incidence (3 and 9 of 19; P = .08) in mice without tumor recurrence. Finally, a
third experiment was performed to clarify ambiguous results in the second experiment and consisted
of 2 groups of 40 mice each. In this larger experiment, the results were essentially equal for the sham
and CADUS groups. Conclusions. Overall, the results do not support the hypothesis of CADUS-
enhanced metastasis. Key words: adverse effects; cancer; contrast agent; diagnostic ultrasound;
metastasis.
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Abbreviations
CADUS, contrast-aided diagnostic ultrasound; PRPA,
peak rarefactional pressure amplitude
etastasis of cancer by hematogenous or lym-
phatogenous spread can be augmented by
perturbations of tumors, which result in the
release of malignant cells. The accidental
spread of malignant cells is a concern in medical proce-
dures that disturb the tumor microvasculature, such as
surgery and biopsy.1 Diagnostic or therapeutic medical
procedures using ultrasound are generally not expected
to enhance metastasis because the imaging or therapy
per se does not appear to have any metastatic mecha-
nism. For example, high-intensity focused ultrasound,
which is used to treat tumors by generating heat coagula-
tion, has been shown not to induce detectable metastasis
or tumor cell release.2,3 However, ultrasound can cause
mechanical perturbation of the microvasculature if the
ultrasound induces acoustic cavitation. Extracorporeal
shock wave lithotripsy is a high-amplitude therapeutic
modality primarily for treatment of kidney stones, but
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research has been conducted on therapy of other
targets. Shock wave lithotripsy treatment has
shown some promise in application to cancer
tumor therapy.4,5 The extremely high pressure
amplitudes used by lithotripsy systems can
induce acoustic cavitation in tissue,6 leading to
hemorrhage in the lung,7 intestine,8 and even
non–gas-bearing tissues such as the kidney.9
Most studies of shock wave tumor treatment
have not reported increased metastasis; however,
a direct test of this potential adverse side effect of
shock wave tumor treatment showed that this
modality has a tendency for an increase in
metastasis from the treatment of highly malig-
nant tumors.10 This report was recently con-
firmed by a different tumor model.11 The use of
enhanced nucleation of acoustic cavitation by
intratumoral injection of an ultrasonographic
contrast agent yielded enhancement of metasta-
sis, thus specifically linking the effect to in vivo
cavitation.11
Commercial contrast agents for diagnostic ultra-
sonography contain gas bodies (stabilized
microbubbles) to intensify the echogenicity of
blood. The presently available ultrasonographic
contrast agents have been approved for echocar-
diography but have not yet been approved for
radiologic applications such as tumor detection
and characterization in the United States.
Research suggests a role for ultrasonographic con-
trast agents for tumor imaging, particularly for
liver tumors.12 The method compares favorably
with computed tomography for liver lesions.13
Contrast-aided ultrasonography is also valuable
for guiding ablation procedures for liver masses14
and for assessing the outcome of treatment.15
The gas bodies in ultrasonographic contrast
agents have been shown to be efficient cavitation
nucleation agents in vitro and in vivo.16 The inter-
action of diagnostic ultrasound with contrast
agent gas bodies can induce microscale bioef-
fects such as petechial hemorrhage.17,18 On the
basis of the demonstrated ability of shock wave
ultrasound to enhance metastasis by a contrast
agent–aided cavitation mechanism, there is rea-
son to suspect that a similar process might be
possible during contrast-aided diagnostic ultra-
sound (CADUS) examinations. This is particular-
ly true for relatively high pressure amplitudes
and low frequencies, which translate into a high
mechanical index (an index of ultrasound expo-
sure provided on most diagnostic platforms).16 A
full exploration of this concern is needed to pro-
vide guidance for development of the CADUS
imaging method for radiologic applications. The
goal of this study was to test the hypothesis that
CADUS could exacerbate the metastatic spread
of mouse melanoma tumor cells to the lungs.
Materials and Methods
All animal research was conducted with the
approval of the University Committee for the Use
and Care of Animals and the guidance of the Unit
for Laboratory Medicine of the University of
Michigan. The B16 and B16-D5 melanoma cell
lines were used with female C57/bl6 mice to
grow subcutaneous tumors. The D5 cells are
metastatic especially to the lung and have been
used in metastasis research.19 Cells injected into
the tail vein form visible lung metastases after
about 18 days. Established methods were used to
test for enhanced lung metastasis, which have
been used for the study of metastasis resulting
from therapeutic or diagnostic manipulation of
tumors implanted on the hind leg.11,20–22 A sus-
pension of 1 million cells in 0.05 mL was injected
subcutaneously on the right hind leg of each
mouse under ether anesthesia. Treatment was
applied after 10 days of tumor growth.
For ultrasonic scanning, mice were weighed
and anesthetized with an intraperitoneal injec-
tion of ketamine (Ketaset; Aveco Co, Fort Dodge,
IA) at 75 mg/kg and xylazine (Rompun; Mobay
Corp, Shawnee, KA) at 15 mg/kg. The tumor area
was shaved and depilated. The volume of each
tumor was estimated with the use of a digital
caliper to measure the 3 major axes of the tumor
and calculation of the ellipsoidal volume.
Average tumor volumes for each group are listed
in Table 1. The mouse was then mounted on a
plastic board with Velcro (Manchester, NH) strips
with the tumor centered over a 2.5-cm hole in the
board. A wetting agent was applied to the tumor
area to minimize air entrapment. Finally, the
mounting board was set up in a 37°C water bath
for ultrasonic scanning. This arrangement pro-
vided essentially free field conditions for the
ultrasound beam, so that the ultrasound expo-
sure was pertinent to acoustic conditions found
in clinical examinations.
The ultrasonographic contrast agent tested in
this study was Definity (Bristol-Myers Squibb
Medical Imaging, Inc, North Billerica, MA). This
agent contains octafluoropropane gas bodies
(stabilized microbubbles) at a concentration of
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12 × 109/mL with a mean diameter range of 1.1 to
3.3 µm according to the package insert. Each
treatment day, a fresh vial of the agent was mixed
in the VialMix shaker supplied with the agent.
This agent was diluted 100:1 in saline by mixing
10 µL of the agent with saline in a 1-mL syringe.
Four bolus doses of the diluted agent, each 1
mL/kg (10 µl/kg for the stock agent), were then
given by retro-orbital injection with a 25-gauge
needle. The doses were spaced 100 seconds
apart, which was intended to maintain a roughly
constant level of circulating gas bodies through-
out the 400-second ultrasound exposure. The
total dosage of the stock agent was then 40
µL/kg, which was 4 times the normal recom-
mended dosage of 10 µL/kg.
A Vingmed System V unit (GE Healthcare,
Cincinnati, OH) with a cardiac phased array
probe (FPA2.5) was used as the diagnostic ultra-
sonic scanner. The same scanning (ie, exposure)
conditions were used for all experiments. The
imaging parameters in the octave (harmonic
imaging) mode were frequency, 1.5 MHz; depth,
10 cm; focus, 5 cm; power, 0 dB; and frame rate,
30.4 frames per second. The ultrasonic field was
measured by a calibrated hydrophone (model
805 polyvinylidene difluoride bilaminar mem-
brane hydrophone; Sonora Medical Systems,
Longmont, CO) positioned at the tumor location
but without the mouse or mounting board. The
maximum pulse during each scan had a peak
rarefactional pressure amplitude (PRPA) of –2.3
MPa and a duration of 1.45 microseconds.
Because attenuation through the skin would be
expected to be negligible, this corresponds to an
equivalent MI of 1.9 at the tumor. The pulse
amplitude PRPA decreased with distance from
the center of the scan plane with a –6 dB thick-
ness of 4.6 mm perpendicular to the plane,
which was sufficient to cover the small tumors.
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Table 1. Overall Outcome for the Treatment Groups.
Volume, µL Tumor 21-d 28-d
Experiment Group Total (Mean ± SD) Recurrence Survival Survival
1, B16 Sham 20 50 ± 38 5 18 17
CADUS 20 47 ± 46 3 17 16
2, D5 Sham 20 79 ± 63 1 20 19
CADUS 20 105 ± 109 1 20 19
3, D5 Sham 40 77 ± 53 3 39 36
CADUS 39* 71 ± 60 3 38 37
*One mouse was excluded because a visible tumor failed to grow.
Figure 1. Sonograms of a tumor-bearing mouse leg before (A) and after (B) injection of a dose of the contrast agent. The cardiac
probe produces a pie-shaped sector scan image. Note that the small tumor region lights up with the contrast agent, which provided
assurance that the contrast agent was reaching the tumor and interacting with the imaging ultrasound pulses.
A B
(In the direction parallel to the scan plane, the
PRPA was approximately constant for several
centimeters.) For scanning, the mice were
mounted in a warmed water bath. The ultrason-
ic probe was clamped in the water bath and
adjusted to locate the mouse tumor 4.5 cm away
from the transducer face (with the mounting
board ≈5 cm away). An initial real-time image
was obtained at 3.6 MHz to clearly locate the
tumor in the image plane, and then the ultrason-
ic frequency was switched to triggered 1.5-MHz
imaging for CADUS. Image frames were inter-
mittently triggered each 1 second to allow the
contrast agent to refill the tumor circulation after
gas body destruction by the previous frame. Each
triggered frame delivered a single sweep of the
pulsed beam formed by the phased array trans-
ducer (the same as each frame of a 30.4-Hz frame
rate real-time image). Typical images of a tumor
are shown in Figure 1 for 1.5 MHz, which provid-
ed only modest resolution of the tumors (Figure
1A). When the contrast agent was injected
(Figure 1B), the tumor area quickly brightened in
the image frames, and this was apparently more
than the brightening of the surrounding thigh
muscle tissue. This enhanced contrast provided
assurance that the agent was present in the cir-
culation at a concentration sufficient for CADUS.
Sham exposure consisted of a combination of
both control conditions of ultrasound alone and
contrast agent alone: the tumor was scanned
without injection of the contrast agent for 400
seconds, followed by injection of the contrast
agent with the ultrasound off.
After scanning, the mice were removed from the
bath, dried, and allowed to recover in warmed
chambers before return to regular cages. The pri-
mary tumor was surgically removed 1 day after
CADUS. Removal of the primary tumor extends
survival to allow formation of visible lung metas-
tases. After the mice were reanesthetized, this was
accomplished by removal of the leg at the hip and
suture of the skin over the area. Recovery was
aided by intraperitoneal injection of 0.3 mL of
warm saline together with buprenorphine anal-
gesic at 0.1 mg/kg subcutaneously.
The mice were euthanized if a tumor recurred
and reached 3000 µL in volume or at 28 days after
CADUS. Data were collected for mice that survived
at least 21 days. For evaluation, the lungs were
removed and bleached in Fekete solution to bring
out the pigmented lung metastases.11 The metasta-
sis nodules in the lungs were evaluated blind after 2
weeks in the Fekete solution by examination under
a low-power stereo microscope. Experimental
groups included sham and CADUS. Three experi-
ments were conducted: B16 cells with 20 mice in
each group, D5 cells with 20 mice in each group,
and D5 cells with 40 mice in each group. The imag-
ing (exposure) was identical for all experiments.
Statistical comparisons of the mean metastasis
counts were made by the Mann-Whitney rank sum
test, and the occurrence rates were compared by
the z test (SigmaStat 3.1; SPSS Inc, Chicago IL).
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Table 2. Results for Counts and Incidence Rates of Lung Metastasis for Mice Surviving at Least 21 Days and
Without Tumor Recurrence
Metastasis Metastases
Experiment Group n Incidence Incidence P (Mean ± SEM) Count P
1, B16 Sham 15 1
.82
0.31 ± 0.22 .73
CADUS 17 1 1.9 ± 1.1
2, D5 Sham 19 3
.081
0.32 ± 0.22 .063
CADUS 19 9 5.5 ± 2.6
3, D5 Sham 36 9
.94
1.5 ± 0.7 .95
CADUS 35 8 1.2 ± 0.6
Figure 2. Comparison of the mean lung metastasis count for
each group in experiments 2 and 3 with SE bars. The metastasis
incidence in mice surviving at least 21 days without tumor recur-
rence is shown above each bar.
Results
The first experiment using the B16 cell line result-
ed in several early deaths and recurrences of the
primary tumors. The overall outcomes of the
groups are listed in Table 1. The metastases are
compared in Table 2 for the mice surviving at least
21 days and not having a recurrence of the prima-
ry tumor. The mice with tumor recurrence were
excluded from this analysis because the recurrence
would have altered the expected metastasis rate
and did not comply with the primary tumor “cure”
protocol. There was no significant difference
between sham and CADUS results in the first
experiment.
The results of the second experiment using the
D5 cell line are also listed in Tables 1 and 2. This
test had a lower recurrence rate, with only 1 mouse
of each group excluded. The results for the num-
bers of metastases and for the occurrence rate
were both marginally statistically significant (ie,
.05 < P < .1). The numbers of metastasis had a
value of P = .063, and the occurrence rate had a
value of P = .081. The results are plotted in Figure
2. Unfortunately, these results with marginal sig-
nificance precluded any firm conclusion regard-
ing the initial hypothesis. The ambiguity of this
result motivated the third experiment using larger
groups to obtain higher statistical power. The
results of the third experiment are listed in Tables
1 and 2. The sham and CADUS groups essentially
had identical outcomes. This result is also plotted
in Figure 2. The results of the second and third
experiments were not evaluated as pooled groups
(potentially giving an initial total of 60 mice in
each group) because the tumor volumes of the
CADUS group were statistically significantly larger
in the second than in the third experiment, and
results of both experiments were separately nega-
tive (P > .05).
Discussion
This study tested the hypothesis that CADUS of
mouse melanoma tumors could exacerbate the
metastatic spread of tumor cells to the lungs. The
B16 and B16-D5 (metastatic specifically to lung)
melanoma cell lines were implanted on the hind
legs of female C57/bl6 mice. Growing tumors were
scanned in a water bath using 1.5-MHz diagnostic
ultrasound at 1 frame per second with injection of
the Definity ultrasonographic contrast agent at 40
µL/kg. The primary tumor was surgically cured 1
day after ultrasound administration to allow iden-
tification of lung metastases in mice surviving at
least 21 days without tumor recurrence. Three
experiments were performed. In the first experi-
ment with groups of 20 mice, B16 metastasis was
not enhanced. However, in the second experiment
with groups of 20 mice, the metastasis of the D5
tumors was marginally enhanced in terms of both
the numbers of metastases (P = .063) and the inci-
dence rate (P = .081). The larger third experiment
involving groups of 40 mice was intended to clari-
fy the ambiguous results of the second experiment.
The results were essentially equal for the sham and
CADUS groups. Overall, the results show that
CADUS did not increase the metastatic spread of
mouse melanoma tumor cells to the lungs.
Several considerations have a bearing on this
conclusion. The subcutaneous melanoma tumor
model as used in this research may not be suffi-
ciently sensitive to show the metastasis enhance-
ment effect. A tumor model with tumors growing
in the interior of organs might be more sensitive
because of improved vascularity. However, the
melanoma model used here was sufficiently sen-
sitive to allow demonstration of increased metas-
tasis with intratumoral injection of a perflutren
contrast agent (Optison; Amersham Health,
Princeton, NJ) and lithotripter shock wave treat-
ment.11 Another consideration may be the influ-
ence of tumor volume on metastasis. In the
previous study,11 tumor volumes were larger
(≈300 µL) to allow for intratumoral injection of the
agent. In this study, with retro-orbital injection of
Definity into the circulation, tumors were smaller
(≈75-100 µL) to ensure full coverage of the tumor
by the ultrasound scan. The tumor volume may
be important because a relatively large number of
cells must be released to the circulation for suc-
cessful implantation in the lungs due to metastat-
ic inefficiency.23 This consideration might play a
role in the previous positive result11 versus the
negative result in this study. Tumor volume might
also have had a role in the results of the second
versus the third experiment in this study; that is,
the marginally significant results in the second
experiment involved significantly larger tumors
than the negative third experiment. Given the
importance of this question for various ultrasono-
graphic applications of contrast agents, further
research may be warranted to examine the factors
of tumor type, tumor volume, contrast agent type,
and the power level of CADUS needed for metas-
tasis enhancement. 
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